Market research
LYS.PA Lysogene S.A
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- 0.0%
- Beta
- 0.91
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- FR0013233475
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- 0.0%
- Beta
- 0.91
About
About Lysogene S.A
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a research collaboration with the Yeda Research and Development Co Ltd. for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LYS.PA discussion.
5 years, 5 months ago
Lysogene S.A is currently in a long term downtrend where the price is trading 17.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.
Finally, its free cash flow fell by 27.7% to $-5M since the same quarter in the previous year.
Based on the above factors, Lysogene S.A gets an overall score of 1/5.